Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04085315 · ClinicalTrials.gov registry record · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
A Phase 1 study of EGFR Gene Mutation and Lung Cancer Metastatic, sponsored by Collin Blakely.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
- 1
- Study location
NCT04085315 is a Phase 1 study of EGFR Gene Mutation and Lung Cancer Metastatic that is actively recruiting participants, run by Collin Blakely. The registered enrollment target is 38 participants, below the 218-participant average among 9 other EGFR Gene Mutation trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04085315, a Phase 1 study of EGFR Gene Mutation and Lung Cancer Metastatic, is actively recruiting participants, sponsored by Collin Blakely.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be important for the growth of lung cancer. Osimertinib may reduce tumor growth by blocking the action of a certain mutant protein (EGFR). This study may help researchers test the safety of alisertib at different dose levels in combination with osimertinib, and to find out what effects, good and/or bad, it has on EGFR-mutated lung cancer.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Alisertib
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04085315
The ClinicalTrials.gov registry entry for NCT04085315 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 218-participant average among 9 other EGFR Gene Mutation trials with a reported enrollment target (83% lower). The listed sponsor is Collin Blakely, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with EGFR Gene Mutation appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT04085315 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04085315 about?
NCT04085315 is a clinical study titled "Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer". This phase I/Ib trial studies the side effects and best dose of alisertib when given together with osimertinib in treating patients with EGFR-mutated stage IV lung cancer. Alisertib may stop the growth of tumor cells by blocking a specific protein (Aurora Kinase A) that researchers believe may be im...
What is the current status of trial NCT04085315?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2019-11-12. Estimated completion is 2026-12-31.
What conditions does trial NCT04085315 study?
This clinical trial studies the following conditions: EGFR Gene Mutation, Lung Cancer Metastatic.
What interventions are being tested in trial NCT04085315?
The interventions under investigation include: Osimertinib (DRUG), Alisertib (DRUG).
Who is sponsoring clinical trial NCT04085315?
This trial is sponsored by Collin Blakely, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04085315 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for EGFR Gene Mutation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells
RECRUITING · Phase 1
-
Ipilimumab and Nivolumab in Combination With Radiation Therapy in Treating Patients With Stage 2-3 Non-small Lung Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation
ACTIVE NOT RECRUITING · Phase 1
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy
RECRUITING
-
EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.